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Background: An increased risk of metabolic syndrome (MS) has been observed among women with previous
gestational diabetes mellitus (pGDM). Increased inflammatory markers such as C-reactive protein (CRP) and
interleukin 6 (IL-6) usually accompany. We performed this survey to examine the relationship between pGDM and
MS, CRP and IL-6.
Methods: 77 women with pGDM and 67 randomly sampled women free from GDM participated in this study,
2–3 years after index pregnancy. Laboratory and anthropometric measurements were performed. MS was defined
according to ATP III criteria. Statistical analyses were conducted using SPSS 18.
Results: CRP were different between groups with and without pGDM [2.69 (2.86 mg/dl and 1.56 (1.39) mg/dl,
respectively; p < 0.01]. The presence of each MS component by itself was associated with significantly higher CRP
Levels, except for fasting blood glucose. In linear regression models, CRP and IL-6 were significantly associated with
BMI (β =0. 25, 0.23; p < 0.01), waist circumference (β=0. 27, 0.05; p < 0.01) and HOMA-IR (β=0. 39, 0.39; p < 0.01).
After adjustment for age and BMI the occurrence of pGDM in the group with both high CRP and MS was
significantly associated with CRP level (OR= 5.11; CI=1.59-16.43; p < 0.01).
Conclusion: Since CRP and Il-6 were higher in women with both pGDM and MS it appears that the presence of
pGDM with MS components have a synergistic effect on the elevation of serum levels of inflammatory markers
which can be partly as a result of visceral obesity. Further long-term studies are necessary to confirm the
relationship between CRP, IL-6 and MS in women with pGDM.
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Gestational diabetes mellitus is a condition in which
blood glucose level increases during pregnancy [1]. Its
prevalence in Iranian pregnant women is 4.7% [2]. Al-
though women with gestational diabetes mellitus (GDM)
usually revert to normal status after delivery, it has ad-
verse effects on maternal and fetal health [3]. Women
with a history of GDM are at significantly increased risk
of developing type 2 diabetes mellitus [4,5] which is it-
self an important risk factor of cardiovascular diseases* Correspondence: Fakhrzad@tums.ac.ir
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reproduction in any medium, provided the orand the latter is a leading cause of death among these
patients [6]. But it seems that GDM-affected women are
more prone to metabolic syndrome (MS) too [7,8].
Further understanding of the underlying mechanisms
of type 2 diabetes mellitus and its cardiovascular compli-
cations may lead to a better prevention and treatment.
Inflammation may be the missing link between pGDM,
type 2 diabetes mellitus (DM) and MS, as it is associated
with insulin resistance [9]. It has been indicated that
increased inflammation is an independent risk factor for
the development of type 2 DM [10,11]. It also has ad-
verse effects on the vascular system and plays an import-
ant role in increasing cardiovascular risk. Many of these
studies have revealed that inflammation is a criticaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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plaque rupture which result in acute heart attack and
stroke [12,13].
Recent studies have focused on C-reactive protein
(CRP) more than other inflammatory markers. CRP is
a protein that is synthesized by liver which is then
secreted into circulation. It is a critical component of
the immune system and is one of the acute phase pro-
teins that is increased during systemic inflammation. On
average, CRP levels tend to rise with an increase in
blood pressure, smoking and increment in BMI. On the
contrary, thin and athletic subjects have lower levels of
CRP. Studies indicate that the higher the levels of circu-
lating CRP, the higher will be the risk of type 2 DM,
myocardial infarction, stroke and peripheral vascular dis-
ease, too [7]. So, it may be also associated especially with
cardiovascular features of MS [8].
In addition some studies have analyzed the role of IL-
6 in the atherosclerosis process as this marker has a con-
cordance with CRP in the inflammatory response. It is
to say that IL-6 induces CRP production in the liver by
activating Janus kinases. Signal transducers and activa-
tors of transcription subsequently switch on the CRP
gene expression, leading to its production. Interleukin 6
is a single chain protein that is produced by immune
cells. It is a cytokine that provokes a broad range of cel-
lular, physiological and immune responses. This cytokine
is relevant to diabetes mellitus and acute coronary syn-
drome, too [14-16].
Due to relatively high prevalence of pGDM in Iranian
women and its potential complications, we conductedAmong about 10000 pregnant women 
admitted to prenatal clinics of Shariati 
hospital during March 2006 till March 2007 
for about 300 subjects were sent invitation 
letter based on random number table
89 letters returned 
because of wrong 
address or moving
82 subjects were volunteers to
participation
6 subjects excluded 
because of NSAIDS 
consumption
67 subjects signed inform consent and 
were enrolled in the study
Figure 1 Flow of the participants in case and control groups.this survey to find out the association of pGDM and MS
with inflammatory markers such as CRP and IL-6 in a
sample of women with pGDM compared to non-pGDM
ones.Methods
Study population
This is a retrospective cohort study which was conducted
since March until May 2009. Prospective participants were
chosen by recalling pregnant women who had been admit-
ted to prenatal clinics of Shariati Hospital from March
2006 until March 2007. During this period, 268 pGDM
women were admitted to these clinics. Invitation letters
were sent to all of them. 71 letters were returned due to
the wrong address or house moving. 95 subjects volun-
teered to participate but finally only 77 subjects were
recruited for the laboratory tests (Figure 1). Control sub-
jects were chosen from pregnant women attending the
prenatal clinics during the same period. Invitation letters
were sent to 300 subjects based on a random number
table. Only 92 subjects replied and 67 people were
recruited to this study (Figure 1).
Inclusion criteria included: having the history of a live
delivery during last 24–36 months, being 20–45 years
old and having done the 75-gram glucose tolerance test
between 24th –26th weeks of gestation.
Women with diabetes antedating pregnancy, the ones
who were taking aspirin which could influence CRP
levels, having the history of preeclampsia or eclampsia
in each of their pregnancies, and also those who had anFor 268 pregnant women were admitted 
to prenatal clinics of Shariati Hospital, 
were diagnosed GDM during March 
2006 till March 2007 were sent the 
invitation letter
71 letters returned 
because of wrong 
address or moving
91 subjects were volunteers to 
participation
4 subjects excluded 
because of diabetes 
mellitus and 5 subjects 
due to NSAIDS 
consumption
77 subjects signed inform consent and 
were enrolled in the study
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chronic infectious disease were excluded.
All of the enrolled women had performed the glucose
tolerate test during the index pregnancy, which was done
as the measurement of plasma glucose after consumption
of 75 g glucose between the 24th and 26th weeks of gesta-
tion. The classification as having GDM was according to
the World Health Organization (WHO) criteria.
Clinical measurements
Weight was measured in light clothing to the nearest 0.1
Kg (using an electronic scale) and height was measured
without shoes to the nearest 1 cm on a standardized,
wall-mounted height board. Waist circumference was
measured to the nearest 1 centimeter with a non-elastic
flexible tape measure while the subjects were in the
standing position at the end of gentle exploration, lat-
erally on the midway between the lowest portion of the
rib cage and iliac crest, and anteriorly midway between
the xiphoid process of the sternum and the umbilicus
[12] Body mass index (BMI) was calculated as the ratio
of the weight (kg) to the square of height (m2).
Systolic (SBP) and diastolic blood pressures (DBP)
were measured two times by a physician using the Auto-
matic device (Omron 7) which had been calibrated by
mercury sphygmomanometer according to The Seventh
Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood
Pressure (JNC7).
Definition of conditions
The metabolic syndrome was defined according to
The National Cholesterol Education Program’s Adult
Treatment Panel III report (ATP III) criteria [17].
Insulin sensitivity was measured by HOMA-IR using
the Mathew’s simplified formula [18]:
HOMAIR ¼ fasting insulinmUI=ml½ 
 fasting glucosemmol=l½ =22:5
The cut-point for diagnosis of high CRP level was
defined as CRP≥3 mg/dl [19].
Biochemical measurements
Blood samples were collected into venoject tubes after
an overnight fast (12 hours). The drawn samples were
then transferred into EDTA tubes, and immediately
placed in an ice box. The plasma was separated by
centrifuging the samples at 2000 rpm, which was imme-
diately sent to the biochemical laboratory and stored at -
60C until being assayed. Glucose was measured using
the enzymatic colorimetric method. Total cholesterol,
high density lipoprotein, low density lipoprotein and tri-
glycerides were measured by the enzymatic method.These measurements were performed by the auto -
analyzer (Hitachi Manneheim 902, Germany). CRP was
measured using an ELISA with a sensitivity of .05 mg/L
and the intra-assay coefficients of variation of 5%. C-
reactive protein values were measured in duplicate, and
the average value was reported for both assays. Plasma
adiponectin concentrations were measured by a vali-
dated sandwich ELISA using an adiponectin-specific
antibody. The intra-assay and inter-assay coefficients of
variation were 3.8% and 7.9%, respectively. Insulin was
measured by radioimmunoassay method (Monobind,
USA). Plasma interleukin-6 levels were measured by en-
zyme linked immunosorbent assay (Cayman, USA). The
detectable limit for interleukin-6 was 0.10 pg/ml, and
the inter-assay coefficient of variation was 7%.
Statistical analysis
Statistical analyses were performed using SPSS 18.0;
PASW statistics. All variables except for CRP had a nor-
mal distribution. So Manne-Whitney U test and medians
were used. Data are given as a % or mean ± standard de-
viation (SD). All statistical comparisons were considered
significant if the p values were less than 0.05 ( p < 0.05).
In case of normality in the distribution of variables, the
two-tailed Student’s t-test was employed to compare two
sets of quantitative data. The Chi-square test was used
to compare the observed frequency between groups as
far as qualitative variables were concerned. Multiple lo-
gistic regressions were carried out to evaluate Odds
Ratio (OR).
Ethical considerations
This study was conducted according to the principles
outlined in the Declaration of Helsinki. All participants
signed a written consent which was approved by the
ethical committee of Endocrinology and Metabolism
Research Institute (EMRI) affiliated to Tehran University
of Medical Sciences. Interpretation of Laboratory and
paraclinical data was provided for all participants and if
necessary they were referred to a specialist for more
management.
Results
Mean age of the participants was 32.33 ± 5.46 (31.66
years ± 5.51 and 32.87 years ± 5.40 in control and pGDM
groups respectively; p=0.19). The laboratory data and
clinical characteristics of the 144 subjects, based on the
history of GDM, are shown in Table 1. In a logistic regres-
sion model the metabolic syndrome was entered as a
dependent variable of pGDM. The odds ratio of metabolic
syndrome was 3.68 (1.25-10.70) after adjustment for age
and BMI. The most frequent metabolic trait was abdom-
inal obesity (61% in pGDM women and 28.4 in the control
group) and the least frequent one was high blood glucose
Table 1 Clinical and laboratory characteristics of study participants
pGDM N = 77 Control N = 67 Value
Age (yr) 32.87 (5.40) 31.66 (5.51) NS
Income (%) <600$ 77.9 89 NS
600-900$ 18.2 7.5
>900$ 3.9 3
Education (%) Less than diploma 29.9 26.9 NS
High-school diploma 50.6 53.7
College education 19.5 19.4




History of diabetes in family (%) 46.8 13.6 0.00
BMI (kg/m2) 28.03 ± 3.61 27.29 ± 5.74 NS
Waist circumference (cm) 91.35 ±9.69 82.84 ± 10.23 0.00
Systolic Blood Pressure (mmHg) 121.35 ± 14.45 108.31 ± 13.16 0.00
Diastolic Blood Pressure (mmHg) 77.19 ± 10.17 73.11 ± 8.90 0.01
FBS (mg/dl) 97.07 ± 15.80 91.19 ± 15.37 0.02
HDL-C (mg/dl) 48.00± 8.57 49.90 ± 8.89 NS
Teiglyceride (mg/dl) 103.28 ± 55.99 123.69 ± 63.01 0.04
Fasting Insulin (mU/ml) 12.01 ± 5.29 7.19 ± 4.62 0.00
hs-CRP (mg/dl) (Median) 2.69 ± 2.86 1.56 ± 1.39 0.00
HOMA-IR 2.88 ± 1.31 1.57 ± 1.02 0.00
LDL-C (mg/dl) 104.09 ± 25.53 87.32 ± 16.81 0.00
IL-6 (pg/ml) 3.56 ± 2.68 2.69 ± 1.77 0.03
Uric-Acid (mg/dl) 4.81 ± 1.12 4.50 ± 1.05 NS
Metabolic Syndrome (%) 9 31.2 0.00
Homocysteine (μmol/dl) 8.19 ± 4.24 8.71 ± 2.35 0.58
Data are expressed as mean ± SD or n (%).
pGDM: Previous Gestational Diabetes, BMI: Body Mass Index, FBS: Fasting Blood Sugar, HDL: High Density Lipoprotein, hsCRP: high sensitive C-reactive Protein,










Figure 2 The prevalence (%) of the components of metabolic
syndrome in pGDM and control groups.
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controls there were not any significant differences in most
of the variables studied, except for some components of
MS (i.e. waist circumference, TG, systolic and diastolic
blood pressure), which were predictable (Figure 2). In
comparison with controls, those with pGDM had a more
prevalent history of type 2 diabetes mellitus in their family,
which was acceptable considering the role of family his-
tory in the occurrence of type 2 diabetes mellitus [20].
There was an association between fasting serum insulin
and also HOMA-IR with CRP in all the participants
(β=0.28, p=0.00 and β=0.35, p=0.00 respectively). This as-
sociation remained significant after adjustment for age
and BMI.
Mean CRP levels were different between groups with
and without pGDM (2.69 ± 2.86 mg/dl and 1.56±1.39
mg/dl, respectively; p < 0.01 - Table 1). The prevalence of
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er than the control group (31.2% and 9% respectively;
p < 0.01).
In another analysis we compared CRP levels based on
individual components of MS in the whole participants
of our study free of having MS or not. We found that
the presence of each MS component by itself is asso-
ciated with significantly higher CRP Levels, except for
fasting blood glucose (data not shown).
CRP levels were also significantly higher in those with
higher BMI (1.33±0.79 mg/dl in those with BMI < 25 kg/
m2 vs. 2.48±2.82 mg/dl in those with BMI≥25 kg/m2;
p < 0.01).
In next step all participants were divided into 6 groups
based on the number of MS components. According to
Figure 3, there was a linear increase in CRP levels with
an increase in the number of MS components in the
group of women with previous GDM. Women with five
MS components, have on average, CRP levels four times
higher than those with four MS components. In linear
regression models, CRP was associated significantly with
BMI (β =0.25, p < 0.01), waist circumference (β = 0.27,
p < 0.01) and HOMA-IR (β=0.39, p < 0.01). Also the asso-
ciations between interleukin 6 and BMI, waist circumfer-
ence and HOMA-IR were assessed (β =0.23, p = 0.05;
β =0.39, p < 0.01 and β = 0.58, p < 0.01; respectively).
Then the participants were categorized into 4 groups
based on the presence or absence of pGDM and MS cri-
teria. The first group had neither the history of GDM,
nor the criteria of MS; the second group had the criteria
of MS but not the history of GDM; the third group was
vice versa and the last group had both the history of
GDM and the criteria of MS. The mean of CRP levels,
HOMA-IR indices and serum interleukin 6, FBS, HDL-C
and LDL-C levels in these 4 groups are shown in Table 2.
There were significant differences in the mean levels of
CRP, HOMA-IR, interleukin 6, HDL-C and LDL-C in a








Figure 3 Mean serum level of CRP with increase of
MS components.was a significant difference between the CRP levels of
the first group (No GDM/No MS) and the fourth group
(who had both history of pGDM and criteria of MS). Al-
though there was also a difference in the mean level of
CRP between the first and the third group (No Ms but
with GDM), it wasn’t statistically significant (p=0.20).
The association between CRP level and pGDM and also
MS was assessed using the multiple logistic model in
which the first group was set as the reference (Table 3).
The analyses revealed that the Odds ratio (OR) of the
second group was 1.29; [Confidence interval (CI) =
0.43−3.82], the third group was 2.38; [CI=0.39−14.19]
and the fourth group was 4.76; [CI=1.54−14.66]. After
adjustment for age and BMI, the occurrence of pGDM
in the fourth group was significantly associated with
CRP level [OR= 5.11; CI = 1.59-16.43].
Discussion
Several studies have shown a strong correlation between
pGDM and MS. Even Anila Verma et al. and Baris
Akinci et al. have postulated pGDM as a risk factor for
development of metabolic syndrome [21,22]. On the
other hand, L. Chatzi and his colleagues have suggested
that metabolic syndrome in first trimester could be a
risk factor for the development of GDM in late preg-
nancy [23]. Also in a prospective study by Wolf et al. it
was shown that high CRP levels in the first trimester of
pregnancy are associated with the increased risk of
pGDM, independent from other risk factors such as age,
multiparity and smoking [9]. In our research we have
tried to explain this discrepancy in means of MS, pGDM
and inflammatory markers.
In this investigation the prevalence of MS in women
with pGDM was about three folds higher than the control
group, which is in concordance with the findings of other
studies such as Lauenborg’s [24]. In our study, the mean
serum levels of CRP, interleukin 6, HOMA-IR and LDL-C
in pGDM women were higher than the control group.
Since the increase in these markers is shown to be a risk
factor for cardiovascular diseases, this could explain the
findings of some studies in which pGDM was defined as a
chronic condition that leads to the increased risk of car-
diovascular disease [6-8]. Winzer et al. in their study
found that in women with pGDM and metabolic syn-
drome, interleukin-6 level was higher than the group with-
out metabolic syndrome and pGDM [25].
According to the findings of this study, the mean
levels of CRP were higher in women with BMI ≥ 25 kg/
m2 than those who had BMI<25 kg/m2. Several epi-
demiological studies have shown a strong correlation be-
tween CRP levels and BMI: the higher the BMI, the
higher the level of CRP [26-28]. However, Ferraz et al.
could not find this correlation although they found out
that the mean CRP levels in women with high waist
Table 2 Mean of risk factors in each group and comparison of them
Group 1 Group 2 Group 3 Group 4 p Adjusted
p*N = 29 N = 9 N = 83 N = 23
No pGDM no MS MS without pGDM pGDM without MS pGDM with MS
CRP mg/dl 1.40 (0.93) 1.97 (1.65) 2.81 (3.03) 4.18 (4.08) < 0.01 < 0.01
Interleukin 6 mg/dl 2.02 (1.30) 2.30 (1.76) 3.32 (1.82) 6.39 (5.00) < 0.01 < 0.01
HOMA-IR 1.53 (1.03) 2.41 (0.96) 2.31 (1.12) 4.01 (1.42) < 0.01 < 0.01
FBS mg/dl 88.29 (11.16) 91.98 (9.77) 95.87 (12.69) 107.64 (20.37) < 0.01 < 0.01
LDL-C mg/dl 87.40 (17.50) 101.46 (23.05) 86.50 (10.60) 109.56 (29.82) 0.02 < 0.01
HDL-C mg/dl 51.46 (7.95) 51.00 (7.98) 37.75 (6.79) 41.76 (6.13) < 0.01 < 0.01
BMI kg/m2 25.13 (4.35) 27.33 (3.50) 31.39 (4.81) 29.47 (3.49) < 0.01 < 0.01§
WC cm 81.09 (9.05) 88.44 (8.96) 95.13 (8.23) 97.40 (8.39) < 0.01 < 0.01
*Adjustment for age and body mass index.
§Adjusted for age.
CRP: C-reactive protein, HOMA-IR: Homeostasis Model Assessment–Insulin Resistance, FBS: Fasting Blood Sugar, LDL-C: Low Density Lipoprotein-Cholesterol, HDL:
High Density Lipoprotein-Cholesterol, BMI: Body Mass Index, WC: Waist Circumference.
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low waist circumference (with the cut-off of 88 cm) [8].
As we have shown C-reactive protein was not inde-
pendently correlated with fasting blood glucose levels.
This is in accordance with a study in Brazilin women
[8]. However, King et al. [29] showed a significant correl-
ation between CRP and FBS. This discrepancy might be
ascribed to the differences in methodology, which means
the lag time between the survey and delivery, and
method of participant selection. For the former reason it
is to say that since our examination was carried out earl-
ier than the other studies (12–24 months after delivery
compared with 5–11 years after delivery this shorter lag
time might have caused this discrepancy. It comes from
other studies that there is a correlation between this lag
time and the development of diabetes. The longer this
period, the higher will be the incidence of type 2 DM
[5,30]. Also, diabetic women had been excluded from
our study.
As we have shown, the known risk factors of subclin-
ical atherosclerosis or cardiovascular disease such as
mean levels of CRP, interleukin 6, HOMA-IR, FBS, and
LDL-C were compared between the four groups with
following features: the first group: without history of
GDM and MS, the second group: women with pGDM
but without MS; the third group: women with MS butTable 3 Association of high CRP with pGDM and MS in
logistic regression model
Odds ratio CI of odds ratio p
Group 1 (No pGDM no MS) 1
Group 2 (MS without pGDM) 1.89 0.50-6.19 0.19
Group 3 (pGDM without MS) 3.46 0.54-21.93 0.18
Group 4 (pGDM with MS) 13.23 3.94 - 44.41 0.00
CRP: C-reactive Protein, pGDM: Pervious Gestational Diabetes, MS: Metabolic
Syndrome, CI: Confidence Interval.without the history of pGDM; and the last group: women
with both MS and the history of pGDM.
There has also been a positive correlation between the
number of MS components and CRP level, so that in
those who have all five components of MS, CRP levels
are four times higher than those who have only four
components of it. This finding is in concordance with
that of Ferraz et al. [8]. There were also similar findings
about interleukin 6 in our investigation (the results are
not shown).
The relationship between inflammatory markers,
pGDM and metabolic syndrome has been poorly stud-
ied. We could not find any differences in CRP levels be-
tween the first group (i.e. without the history of pGDM
and MS) and the second group (only with the history of
pGDM/without MS). Additionally, there was no signifi-
cant difference in CRP level of the first and the third
group (without MS and history of pGDM, and with MS
without history of pGDM, respectively). But the first and
fourth group (women with pGDM and MS) were differ-
ent in terms of CRP level. It means, CRP was higher
when the history of pGDM and MS were present com-
pared with those without these two components. The
results of this study revealed that in pGDM women who
have MS components too, CRP levels increase more
than 5 times, compared with women without MS and
pGDM. Considering interleukin 6 concentrations be-
tween the 4 mentioned groups, it was shown that the
mean level of interleukin 6 in the fourth group was
about 2 times higher than the third and second groups.
In addition, we found that BMI and particularly waist
circumference were associated with CRP levels. This is
compatible with studies of other investigators who also
found that when the history of pGDM co-exists with
MS, there is a synergistic effect on the elevation of
serum levels of inflammatory markers. They showed that
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pGDM may be related to visceral obesity. Any increase
in fat tissue, particularly in abdominal viscera, could lead
to the activation of inflammatory cascade [31-34].
Conclusion
It seems that the presence of either the history of pGDM
or MS may result in an increase in inflammatory markers
levels such as CRP and interleukin 6, although it was not
significant. It should be considered that when these two
risk factors are both present they could have a synergistic
effect on the rising of inflammatory markers. We could
detect association of inflammatory markers with BMI,
waist circumference and HOMA-IR as well. Further long-
term studies are necessary to confirm the correlation of
CRP and MS in women with pGDM and the potential life-
style and/or pharmaceutical interventions.
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